Omenn syndrome is a rare form of severe combined immunodeficiency characterized by immune dysregulation, recurrent infections, erythroderma, eosinophilia, and failure to thrive. Hematopoietic stem cell transplantation (HSCT) remains the definitive treatment; however, outcomes are particularly challenging in patients with active severe infections before transplantation. Here, we report the case of a female infant who presented with persistent diarrhea and recurrent otitis media at 2 months of age and was diagnosed at 3 months with genetically confirmed Omenn syndrome caused by a homozygous pathogenic RAG1 variant (c.1187G>A; p.Arg396His). Her clinical course was complicated by recurrent multidrug-resistant bacterial bloodstream infections, Candida auris fungemia, acute kidney injury, disseminated intravascular coagulation, and respiratory failure requiring pediatric intensive care admission. Because she was clinically unstable for conventional conditioning chemotherapy, she underwent unconditioned matched unrelated donor peripheral blood stem cell transplantation at 8 months of age. Despite persistent mixed donor chimerism and absent B-cell engraftment, she demonstrated progressive donor-derived T-cell recovery, normalization of CD4/CD8 ratio, resolution of recurrent infections, and sustained clinical stability. To our knowledge, reports describing unconditioned matched unrelated donor HSCT in genetically confirmed Omenn syndrome complicated by multidrug-resistant bacterial infections and Candida auris fungemia remain extremely limited. This case highlights that unconditioned HSCT may provide clinically meaningful immune reconstitution when standard conditioning is not feasible.
Citation: F Malaeb, I Sanduqji, F Manjomi, M Alzahrani, M Alsultan. Successful T-cell engraftment following unconditioned matched unrelated donor transplant in a child with Omenn syndrome and recurrent multidrug-resistant infections: A case report[J]. AIMS Allergy and Immunology, 2026, 10(2): 108-115. doi: 10.3934/Allergy.2026009
Omenn syndrome is a rare form of severe combined immunodeficiency characterized by immune dysregulation, recurrent infections, erythroderma, eosinophilia, and failure to thrive. Hematopoietic stem cell transplantation (HSCT) remains the definitive treatment; however, outcomes are particularly challenging in patients with active severe infections before transplantation. Here, we report the case of a female infant who presented with persistent diarrhea and recurrent otitis media at 2 months of age and was diagnosed at 3 months with genetically confirmed Omenn syndrome caused by a homozygous pathogenic RAG1 variant (c.1187G>A; p.Arg396His). Her clinical course was complicated by recurrent multidrug-resistant bacterial bloodstream infections, Candida auris fungemia, acute kidney injury, disseminated intravascular coagulation, and respiratory failure requiring pediatric intensive care admission. Because she was clinically unstable for conventional conditioning chemotherapy, she underwent unconditioned matched unrelated donor peripheral blood stem cell transplantation at 8 months of age. Despite persistent mixed donor chimerism and absent B-cell engraftment, she demonstrated progressive donor-derived T-cell recovery, normalization of CD4/CD8 ratio, resolution of recurrent infections, and sustained clinical stability. To our knowledge, reports describing unconditioned matched unrelated donor HSCT in genetically confirmed Omenn syndrome complicated by multidrug-resistant bacterial infections and Candida auris fungemia remain extremely limited. This case highlights that unconditioned HSCT may provide clinically meaningful immune reconstitution when standard conditioning is not feasible.
| [1] | Haddad E, Hoenig M (2018) Hematopoietic stem cell transplantation for severe combined immunodeficiency (SCID). Front Pediatr 6: 486. https://doi.org/10.3389/fped.2018.00486 |
| [2] | Pai SY, Logan BR, Griffith LM, et al. (2019) Transplantation outcomes for SCID: The 50-year experience at CIBMTR. J Allergy Clin Immunol 143: 757-766. https://doi.org/10.1016/j.jaci.2018.07.036 |
| [3] | Martinez C, Solano C, Sierra J (2012) Hematopoietic cell transplantation for primary immunodeficiencies. Curr Opin Hematol 19: 451-458. https://doi.org/10.1097/MOH.0b013e328358bdd3 |
| [4] |
Cipe FE, Dogu F, Aytekin C, et al. (2012) HLA-haploidentical transplantations for primary immunodeficiencies: A single-center experience. Pediatr Transplant 16: 451-457. https://doi.org/10.1111/j.1399-3046.2012.01703.x 
|
| [5] | Kohn DB, Booth C, Kang EM, et al. (2020) Gene therapy and allogeneic hematopoietic stem cell transplantation for primary immunodeficiency diseases. Blood 136: 2623-2635. https://doi.org/10.1182/blood.2020006588 |
| [6] |
Chow JK, Golan Y, Ruthazer R, et al. (2008) Risk factors for Candida bloodstream infection in the ICU. Crit Care Med 36: 2967-2972. https://doi.org/10.1097/CCM.0b013e31818b3602
|
| [7] |
Satlin MJ, Jenkins SG, Walsh TJ (2014) The global emergence of carbapenem-resistant Enterobacteriaceae in transplant recipients. Curr Infect Dis Rep 16: 436. https://doi.org/10.1007/s11908-014-0436-9
|
| [8] | Slack J, Albert MH, Balashov D, et al. (2021) Reconstitution of immunity after HSCT in SCID: T-cell function more important than full chimerism. Blood Adv 5: 1570-1580. https://doi.org/10.1182/bloodadvances.2020003319 |
| [9] |
Lankester AC, Albert MH, Booth C, et al. (2021) EBMT/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity. Bone Marrow Transplant 56: 2052-2062. https://doi.org/10.1038/s41409-021-01378-8
|
| [10] | Heimall J, Logan BR, Cowan MJ, et al. (2017) Immune reconstitution and survival of 100 SCID patients post-HSCT. J Allergy Clin Immunol 139: 2092-2101. https://doi.org/10.1016/j.jaci.2016.11.047 |
Figures(2)
F Malaeb, I Sanduqji, F Manjomi, M Alzahrani, M Alsultan. Successful T-cell engraftment following unconditioned matched unrelated donor transplant in a child with Omenn syndrome and recurrent multidrug-resistant infections: A case report[J]. AIMS Allergy and Immunology, 2026, 10(2): 108-115. doi: 10.3934/Allergy.2026009
DownLoad: